Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.

Authors

David S. Weinberg, Fox Chase Cancer CenterFollow
Jieru E. Lin, Thomas Jefferson UniversityFollow
Nathan R. Foster, Mayo Clinic
Gary Della'Zanna, NIH
Asad Umar, NIH
Drew Seisler, Mayo Clinic
walter K. Kraft, Thomas Jefferson UniversityFollow
David M. Kastenberg, Thomas Jefferson UniversityFollow
Leo C. Katz, Thomas Jefferson UniversityFollow
Paul J. Limburg, Mayo Clinic
Scott A. Waldman, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

6-1-2017

Comments

This article has been peer reviewed. It is the author’s final published version in Cell Death and Disease Volume 5, Issue 3, March 2014, Article number e1151.

The published version is available at DOI: 10.1038/cddis.2014.117. Copyright © Nature Publishing Group

Abstract

Guanylate cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of its luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention agent. Linaclotide is an FDA-approved oral GUCY2C agonist formulated for gastric release, inducing fluid secretion into the small bowel to treat chronic idiopathic constipation. The ability of oral linaclotide to induce a pharmacodynamic response in epithelial cells of the colorectum in humans remains undefined. Here, we demonstrate that administration of 0.87 mg of oral linaclotide daily for 7 days to healthy volunteers, after oral colon preparation with polyethylene glycol solution (MoviPrep), activates GUCY2C, resulting in accumulation of its product cyclic (c)GMP in epithelial cells of the cecum, transverse colon, and distal rectum. GUCY2C activation by oral linaclotide was associated with homeostatic signaling, including phosphorylation of vasodilator-stimulated phosphoprotein and inhibition of proliferation quantified by reduced Ki67-positive epithelial cells. In the absence of the complete oral colonoscopy preparation, linaclotide did not alter cGMP production in epithelial cells of the colorectum, demonstrating that there was an effect related to the laxative preparation. These data show that the current FDA-approved formulation of oral linaclotide developed for small-bowel delivery to treat chronic idiopathic constipation is inadequate for reliably regulating GUCY2C in the colorectum to prevent tumorigenesis. The study results highlight the importance of developing a novel GUCY2C agonist formulated for release and activity targeted to the large intestine for colorectal cancer prevention. Cancer Prev Res; 10(6); 345-54. ©2017 AACR.

Recommended Citation

Weinberg, David S.; Lin, Jieru E.; Foster, Nathan R.; Della'Zanna, Gary; Umar, Asad; Seisler, Drew; Kraft, walter K.; Kastenberg, David M.; Katz, Leo C.; Limburg, Paul J.; and Waldman, Scott A., "Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention." (2017). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 83.
https://jdc.jefferson.edu/petfp/83

PubMed ID

28396341